摘要
目的系统性分析苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压的有效性与安全性。方法从1966至2020年7月Pubmed、Embase、Medline、Cochrane图书馆、中国期刊全文数据库及万方数据知识服务平台等电子数据库,检索"苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压"的随机对照试验文献,并对文献结果进行Meta分析,采用Review Manager 5.3软件对提取的数据进行统计分析,研究选择和数据提取由两位作者独立完成。结果与服用单一苯磺酸左旋氨氯地平比较,苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压的有效率显著提高(OR=5.25,95%CI=3.64~7.58,P<0.001);苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压可使得舒张压显著降低(MD=-12.50,95%CI=-13.81~-11.20,P<0.001);苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压可使得收缩压显著降低(MD=-7.04,95%CI=-8.76~-5.33,P<0.001);苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压可使得BMI显著降低(MD=-3.13,95%CI=-3.38~-2.87,P<0.001);苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压的不良反应率显著降低(OR=0.20,95%CI=0.08~0.46,P<0.001)。结论苯磺酸左旋氨氯地平联合二甲双胍治疗肥胖型高血压效果显著,且不良反应不明显。
Objective To systematically analyze the efficacy and safety of levamlodipine besylate combined with metformin in the treatment of obese hypertension. Methods From 1966 to 2020 July in Pubmed, Embase, Medline and the Cochrane library, China hownet(CNKI) and Electronic databases such as the Chinese Journal Full-text Database and Wanfang Data Knowledge Service Platform, the literature of randomized controlled trials of "levamlodipine besylate combined with metformin in the treatment of obese hypertension" were searched, and a Meta-analysis of the literature results were analyzed. Review Manager 5.3 software was used to perform statistical analysis on the extracted data. Research selection and data extraction were done independently by 2 authors. Results Compared with taking single levamlodipine besylate, the effective rate of levamlodipine besylate combined with metformin in the treatment of obese hypertension was significantly improved(OR=5.25, 95% CI=3.64-7.58, P < 0.001);L-Amlodipine besylate combined with metformin in the treatment of obese hypertension can significantly reduce the diastolic blood pressure(MD=-12.50, 95% CI=-13.81--11.20, P<0.001);L-Amlodipine besylate Dipine combined with metformin in the treatment of obese hypertension can significantly reduce systolic blood pressure(MD=-7.04, 95% CI=-8.76--5.33, P<0.001);levamlodipine besylate combined with metformin in the treatment of obesity hypertension blood pressure can significantly reduce BMI(MD=-3.13, 95% CI=-3.38--2.87, P<0.001);the adverse reaction rate of levamlodipine besylate combined with metformin in the treatment of obese hypertension is significantly reduced(OR=0.20, 95% CI=0.08-0.46, P < 0.001). Conclusion Levamlodipine besylate combined with metformin has a significant effect on the treatment of obese hypertension, and the side effects are not obvious.
作者
蓝巧花
鲁灵龙
LAN Qiao-Hua;LU Ling-Long(The General Clinic of Shangcheng Community Health Service Center in Yuanvuan City,Hevuan 517099,China;Guangdong Maternal and Child Health Care Hospital,Guangzhou 511446,China)
出处
《中国药物经济学》
2021年第4期82-86,共5页
China Journal of Pharmaceutical Economics
